SecBot SecBot
424B5 ·Filed Apr 6, 2026

ONCY

ONCOLYTICS BIOTECH INC
BEARISH
Impact 6/10
Horizonimmediate Processed7mo ago SEC0001104659-26-039932
Notable filing: 424B5
Actionable Insight ▼ Bearish

Monitor the pace and pricing of share sales, as the at-the-market structure allows for opportunistic selling that could pressure the stock price. The offering follows a recent shelf registration, indicating potential for future dilution. The company's going concern warning in its financials adds risk to the capital raise strategy.

DirectionBearish
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$0.9000
T+0 close · Apr 6, 2026 · via day close
Latest settled
−0.10%
T+60 · $0.8991
Vs SPY
−13.37%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 7 $0.9000entry
  2. T+1 · 7mo ago +1.11%α −1.43% · $0.9100
  3. T+5 · 7mo ago +13.33%α +8.00% · $1.02
  4. T+20 · 7mo ago +3.33%α −6.45% · $0.9300
  5. T+60 · 5mo ago −0.10%α −13.37% · $0.8991
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Oncolytics Biotech is conducting an at-the-market offering of up to $75 million in common stock through Jefferies, following a $250 million shelf registration. The company plans to use the proceeds for clinical development of pelareorep and general corporate purposes. This offering follows a recent shelf registration and represents potential future dilution.

Key Facts

  • Oncolytics Biotech is offering up to $75 million in common stock through an at-the-market offering with Jefferies
  • The offering is part of a $250 million shelf registration filed on April 1, 2026
  • Proceeds will fund clinical development of pelareorep, research and development, operating costs, and general corporate purposes
  • The offering price is up to $0.96 per share, with an expected issuance of up to 78,125,000 shares
  • Investors will experience immediate dilution of $0.59 per share
  • The company has a market cap of $103 million and reported net tangible book value of $(3.8) million as of December 31, 2025

Financial Impact

Up to $75 million in gross proceeds with potential for significant dilution

dilutiondebtequity

Risk Factors

  • Immediate dilution of $0.59 per share for new investors
  • Potential for further dilution if the company issues additional shares
  • The company's financial statements include an explanatory paragraph about conditions that raise substantial doubt about its ability to continue as a going concern

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
424B5 Filing (Primary)0001104659-26-039932
Document: 0001104659-26-039932-index-headers.html0001104659-26-039932
Document: 0001104659-26-039932-index.html0001104659-26-039932
Document: 0001104659-26-039932.txt0001104659-26-039932

US Market Status

Market Closed · Opens in 6h 41m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 6, 2026